REGENERATIVE CELL THER­APY: WHO WILL BEN­E­FIT?

Stardust (English) - - NEWS -

Joint pain is now a chronic prob­lem amongst young peo­ple and is caused by a num­ber of fac­tors such as phys­i­cally stren­u­ous jobs, in­juries, trau­matic ac­ci­dents or seden­tary life­style. Cur­rently, these in­di­vid­u­als are ad­vised tem­po­rary mea­sures such as painkillers and phys­io­ther­apy to abate their joint pain. This is be­cause knee or hip re­place­ment surgery may not be ad­vis­able for in­di­vid­u­als up to 55 years of age. How­ever, if the di­ag­no­sis re­veals early stage tis­sue dam­age, these peo­ple may be at risk of de­vel­op­ing os­teoarthri­tis. Now, with Regenerative Cell Ther­apy from RMS Re­grow , these pa­tients can get a natural and per­ma­nent so­lu­tion to their car­ti­lage and bone prob­lems.

CHONDRON – Car­ti­lage Cell Ther­apy

Car­ti­lage is the soft tis­sue present in all the joints of the body such as knee, an­kle, shoul­der, etc. Car­ti­lage once dam­aged, can­not re­pair it­self. This poses risk of per­ma­nent loss of car­ti­lage re­quir­ing knee re­place­ment in fu­ture. To re­gen­er­ate a pa­tient’s car­ti­lage, a small piece of car­ti­lage tis­sue is har­vested and sent to RMS Re­grow lab­o­ra­tory. In 3 weeks, pa­tient spe­cific cells are cul­tured and sent back to the hos­pi­tal for im­plan­ta­tion lead­ing to tis­sue re­gen­er­a­tion, thus al­low­ing the pa­tient to re­gain ac­tive life­style in­clud­ing sports.

OSSRON – Bone Cell Ther­apy

Avas­cu­lar Ne­cro­sis, a bone de­gen­er­a­tive con­di­tion of­ten leads to col­lapse of the hip joint re­quir­ing hip re­place­ment surgery. To re­gen­er­ate a pa­tient’s bone, a small amount of body fluid is ex­tracted and cul­tured over 4 weeks in RMS Re­grow GMP cer­ti­fied lab to cus­tom-pre­pare bone cells. These cells, upon im­plan­ta­tion, form new three di­men­sional bone help­ing the pa­tient get rid of his or her pain. It is im­por­tant to un­der­stand that these two pro­ce­dures are not rec­om­mended for pa­tients with ir­re­versible dam­age of car­ti­lage and bone, and there­fore, most pa­tients in the 65 years+ age group may re­quire joint re­place­ment surgery. To as­cer­tain your suit­abil­ity to un­dergo regenerative cell ther­apy, con­tact your near­est Apollo Hos­pi­tals or­tho­pe­dic con­sul­tant.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.